About US
Contact us
-
GlaxoSmithKline CEO's reform-minded rep under fire in China probeWas GlaxoSmithKline ($GSK) CEOAndrew Wittylooking in the wrong direction when he pledged to clean up his company's act? As theWall Street Journalreports, Witty has focused heavily on reforming the com2013/8/7
-
New data for Bayer, Regeneron drug Eylea may help it gain ground from LucentisBayer's eye drugEyleahas already enjoyed a wealth of success since its approval, and now it looks to be in for much more. The company has announced positive late-stage study data that could put the dr2013/8/7
-
2014’ PHEXCOM Events Schedule2014’ PHEXCOM Events Schedule Dear VIP members： For the sake of providing better service to satisfy your demand, we prepared the “ 2014 PHEXCOM Events schedule”. Please mark “√”on “□” which you2013/8/6
-
Roche throws HIV blindness drug Valcyte into patent poolIn the past, Roche ($RHHBY), like Big Pharma companies normally do, has done everything in its power to protect its drugValcytefrom low-cost generic competition. Now, however, the company has signed a2013/8/6
-
GlaxoSmithKline hits speed bump en route to diabetes drug approvalGlaxoSmithKline ($GSK) hit a roadblock in its bid for approval on a newdiabetesdrug. The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's ($N2013/8/6
-
Drug shortage complicates execution schedule for death penalty leader TexasWith 5 executions pending this year, Texas looking for new supply of pentobarbital The big concern when it comes todrug shortagesis whether crucial drugs are going to be available to keep patients al2013/8/5
-
India pulls another patent, this time for GSK's TykerbBoard revokes patent on salt version of cancer drug, upholds it on original API India has regularly been pulling the rug out from under Western drugmakers' intellectual property and has done it again2013/8/5
-
Merck to build biologics research facility in New Jersey where plant will closeNews comes after its reported huge earnings decline this week Merck ($MRK) says it will shutter another plant as it continues to suffer from the patent loss of blockbusterSingulair, but it intends to2013/8/2
-
Sanofi CEO can't sugar-coat 'shocking' Q2 resultsBrazilian snafu, generic competition prompt cut to earnings forecastCall it what you will: chutzpah, optimism, wishful thinking, spin-doctoring, or just plain confidence. In any case, the headline on2013/8/2
-
US scientists make chemotherapy tolerance breakthrough in miceScientists in Michigan have discovered a biological mechanism that can preserve the gastrointestinal tracts of mice after a lethal dose of chemotherapy, a discovery that could lead to better tolerance2013/8/1